Skip to main content
Fig. 5 | Respiratory Research

Fig. 5

From: Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study

Fig. 5

Adjusted geometric mean concentrations (GMCs with 95% confidence intervals) of antibodies against non-typeable Haemophilus influenzae antigens (PD, PE, PilA) and Moraxella catarrhalis antigen (UspA2) (per-protocol immunogenicity cohort). EU, ELISA units; PD, protein D; PE, protein E; PilA, Pilin A; UspA2, ubiquitous surface protein A2. 0–2–6 group was given vaccine at 0–2–6 months and placebo at 12 months; 0–2–12 group was given vaccine at 0–2–12 months and placebo at 6 months. Number of participants with available results at each time point: between 77 and 82 in 0–2–6 group, between 79 and 87 in 0–2–12 group

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us